Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124163 | 1.00 | CHRNB2 (0.56) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4141432 | 0.99 | CHRNB2 (0.55) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4141438 | 0.99 | CHRNB2 (0.55) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4141497 | 0.99 | CHRNB2 (0.55) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4145108 | 0.94 | CHRNB2 (0.51) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4125219 | 0.89 | SLC6A2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4144918 | 0.89 | SLC6A2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4125224 | 0.89 | SLC6A2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4125221 | 0.89 | SLC6A2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4132237 | 0.89 | SLC6A2 (0.51) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | claimed |
| EP-1931653-A2 | THERAPEUTIC PYRROLIDINES | Pfizer Products Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | claimed |
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1931653-A2 | THERAPEUTIC PYRROLIDINES | Pfizer Products Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | OPRL1, HTR5A, OPRD1 | CHRNB2 1057/4885CHRNA4 433/4885SLC6A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.